Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year High - Should You Buy?

Key Points

• Royalty Pharma hit a new 52-week high, trading around $68.43, up from its previous close of $67.56.
• The company raised its 2026 royalty-receipts outlook to $3.55 billion, while adjusted Q3 EPS beat consensus; however, separate coverage reported GAAP EPS and revenue below estimates.
• Analysts’ consensus rating is “Buy,” but their average price target of $61.57 is below the stock’s current level.

Shares of Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) hit a new 52-week high during trading on Thursday. The stock traded as high as $68.20 and last traded at $68.4250, with a volume of 5,165 shares. The stock had previously closed at $67.56.

More Royalty Pharma News

Here are the key news stories impacting Royalty Pharma this week:

• Positive Sentiment: Royalty Pharma raised its 2026 royalty-receipts outlook to $3.55 billion, signaling stronger expected receipts for the year. This is the clearest positive catalyst in the recent coverage. Article: Royalty Pharma Q3 Results Show Growth; Raises FY26 Receipts Outlook
• Positive Sentiment: Adjusted third-quarter earnings were reported at $1.21 per share, above Zacks’ $1.18 consensus, and up from $1.17 a year earlier. That beat may support investor confidence in operating performance. Article: Royalty Pharma Q3 Earnings and Revenues Surpass Estimates
• Neutral Sentiment: A Seeking Alpha analysis highlighted Royalty Pharma’s diversified royalty portfolio and exposure to established biopharmaceutical therapies. This is a longer-term investment case, not a new company announcement. Article: Royalty Pharma: Unique, Diversified Life Science And Biopharma Pure Play
• Negative Sentiment: Some coverage reported GAAP EPS of $0.32 and revenue of $690.1 million, below its cited consensus estimates. These figures differ from the adjusted-EPS comparison above, so investors should distinguish accounting measures and estimate sources when assessing the quarter. Article: Royalty Pharma quarterly earnings results

Analyst Upgrades and Downgrades

RPRX has been the subject of several research reports. Bank of America reiterated a "buy" rating on shares of Royalty Pharma in a report on Wednesday, August 5th. Weiss Ratings upgraded Royalty Pharma from a "buy (b-)" rating to a "buy (b)" rating in a research note on Monday, September 14th. JPMorgan Chase & Co. upped their price target on Royalty Pharma from $58.00 to $62.00 and gave the stock an "overweight" rating in a research note on Friday, August 7th. The Goldman Sachs Group restated a "buy" rating and set a $66.00 price target on shares of Royalty Pharma in a research report on Thursday, August 6th. Finally, Morgan Stanley lifted their price objective on Royalty Pharma from $65.00 to $67.00 and gave the company an "overweight" rating in a research note on Wednesday, October 7th. Eight equities research analysts have rated the stock with a Buy rating. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $61.57.

Royalty Pharma Stock Up 2.7%

The business has a 50-day moving average price of $60.59 and a two-hundred day moving average price of $53.53. The company has a quick ratio of 2.80, a current ratio of 2.80 and a debt-to-equity ratio of 0.88. The firm has a market cap of $39.90 billion, a PE ratio of 47.83, a price-to-earnings-growth ratio of 1.82 and a beta of 0.37.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its earnings results on Wednesday, August 5th. The biopharmaceutical company reported $1.32 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.27 by $0.05. Royalty Pharma had a return on equity of 30.01% and a net margin of 32.14%. The firm had revenue of $674.14 million during the quarter, compared to analyst estimates of $758.93 million. On average, equities research analysts expect that Royalty Pharma PLC will post 5.29 EPS for the current year.

Royalty Pharma Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be paid a dividend of $0.2350 per share. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.4%. The ex-dividend date is Friday, November 13th. Royalty Pharma's dividend payout ratio is presently 64.83%.

Insider Activity at Royalty Pharma

In other Royalty Pharma news, EVP Christopher Hite sold 100,000 shares of the stock in a transaction that occurred on Tuesday, September 22nd. The shares were sold at an average price of $58.53, for a total value of $5,853,000.00. Following the sale, the executive vice president directly owned 270,401 shares of the company's stock, valued at approximately $15,826,570.53. This represents a 27.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 4,126 shares of the firm's stock in a transaction on Monday, October 5th. The shares were sold at an average price of $57.10, for a total transaction of $235,594.60. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 208,252 shares of company stock worth $12,324,407. 18.84% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Royalty Pharma

Institutional investors and hedge funds have recently modified their holdings of the company. Calamos Wealth Management LLC purchased a new stake in Royalty Pharma during the 1st quarter worth about $3,762,000. Monetta Financial Services Inc. purchased a new position in Royalty Pharma in the 2nd quarter valued at about $1,682,000. Dorsey Asset Management LLC lifted its holdings in Royalty Pharma by 0.8% in the 1st quarter. Dorsey Asset Management LLC now owns 2,276,570 shares of the biopharmaceutical company's stock valued at $109,207,000 after purchasing an additional 17,101 shares in the last quarter. TD Waterhouse Canada Inc. lifted its holdings in Royalty Pharma by 121.2% in the 2nd quarter. TD Waterhouse Canada Inc. now owns 81,697 shares of the biopharmaceutical company's stock valued at $4,564,000 after purchasing an additional 44,764 shares in the last quarter. Finally, NewEdge Advisors LLC boosted its stake in shares of Royalty Pharma by 400.2% during the 2nd quarter. NewEdge Advisors LLC now owns 21,597 shares of the biopharmaceutical company's stock worth $1,211,000 after purchasing an additional 17,279 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company's stock.

Royalty Pharma Company Profile

Royalty Pharma plc NASDAQ: RPRX is a biopharmaceutical royalty investment company that provides funding to life sciences companies, academic institutions, and other organizations in exchange for rights to future payments tied to approved or development-stage medicines. Its business model gives innovators access to capital while allowing Royalty Pharma to participate in the long-term commercial success of pharmaceutical products.

The company acquires and manages royalty interests across a broad range of therapeutic areas, including immunology, oncology, neuroscience, rare diseases, and infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.